Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Novartis Pharmaceuticals Corporation and Takeda Oncology.

Expert Illustrations & Commentaries™: Reshaping the Clinical Landscape of HR-MDS Through Novel Mechanisms of Action

Release Date: October 15, 2021
Expiration Date: October 15, 2022

Activity Overview

This edition of Expert Illustrations and CommentariesTM is a video-based program in which 2 experts discuss the dynamic clinical landscape in patients with higher-risk myelodysplastic syndrome (HR-MDS). In this activity, the faculty focus on the pathophysiology and classifications of HR-MDS, as well as the rationale for targeting emerging oncogenic pathways and immune escape mechanisms in clinical trials. Their discussion is enriched with the use of video animations to illustrate novel mechanisms of action of emerging agents. The use of these animated segments helps to make somewhat complicated subject matter more easily understood. This unique format is designed to help clinicians identify best practices in the diagnosis and management of HR-MDS and to improve outcomes for their patients with this disease.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Novartis Pharmaceuticals Corporation and Takeda Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists, hematologists, pathologists, and fellows involved in the treatment of HR-MDS. Nurse practitioners, physician assistants, nurses, pharmacists, and other health care professionals involved in the treatment of HR-MDS will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Illustrate the underlying mechanisms of oncogenic signaling and immune escape in MDS and the rationale for targeting these pathways in the treatment of higher-risk MDS
  • Evaluate efficacy and safety profiles of emerging agents/combinations in patients with higher-risk MDS
  • Implement strategies to monitor and manage toxicities associated with therapeutic approaches in higher-risk MDS

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities


Amy E. DeZern, MD, MHS
Amy E. DeZern, MD, MHS
Director, Bone Marrow Failure and MDS Program
Associate Professor of Oncology
Associate Professor of Medicine
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, MD

Disclosures: Other Support: Taiho, Takeda, Bristol Myers Squibb, Novartis, AbbVie.

Mikkael Sekeres, MD, MS
Mikkael Sekeres, MD, MS
Chief, Division of Hematology
Professor of Medicine
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine
Miami, FL

Disclosures: Other Support: Advisory Board: Bristol Myers Squibb, Novartis, Takeda, Millennium.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By